REGENEREX PHARMA, INC.

Distressed pre-revenue wound-care micro-cap with going concern, near-zero liquidity and promotional disclosure.

Strengths

• Claimed proprietary QBx wound-healing technology with OTC product clearance
• Pursuing state Medicaid and international distribution agreements

Risks

• Going concern; ~$0.65M cash, current ratio 0.13 (5.4th pct) — acute cash-out risk
• No revenue, a $400K theft loss, and ROE 60% is a negative-equity artifact

Notable findings

• No interest coverageInterest coverage -5.71 (cannot cover interest)
• Going concernThese factors raise substantial doubt about the Company’s ability to continue as a going concern
• Exec changeRecent 8-K item 5.02 8-K ↗
• Weak liquidityCurrent ratio 0.13 (<1)